Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

Last updated: May 30, 2024
Sponsor: Rutgers, The State University of New Jersey
Overall Status: Active - Recruiting

Phase

3

Condition

Periodontitis

Treatment

Placebo

Amoxicillin

Metronidazole

Clinical Study ID

NCT06131021
Pro2023001347
4UH3DE031129-02
  • Ages > 40
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Periodontitis is a bacterial inflammatory disease and antibiotic use is being empirically used as part of its treatment. However, a clinical practice guideline on periodontal treatment adjuncts published in 2015 identified weak evidence on the use of systemic antibiotics and large heterogeneity across small scale studies, suggesting that larger pragmatic clinical trials would benefit clinical decision making. This will be a prospective, randomized, placebo-controlled trial, stratified by practice and practitioner. The study will investigate the effectiveness of adjunctive antibiotics as adjunct to scaling and root planing (SRP) compared to SRP with placebo for the treatment of generalized stage II-III, grades A-C periodontitis in approximately 544 patient participants from about 34 National Dental PBRN practices. Periodontal data will be collected at baseline, re-evaluation (6 weeks), and final (12 months) study visits. Changes in periodontal clinical and patient-reported outcomes will be assessed to determine the effectiveness of SRP plus adjunctive systemic Amoxicillin / Metronidazole antibiotics (AMXM) versus SRP with Placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • The study will recruit a target of 544 patient participants presenting forperiodontal treatment within the National Dental PBRN practices participating inthis study.

To be eligible to participate in this study, a potential patient participant must meet all the following criteria:

  • Adult who is at least 40 years old.

  • Presence of ≥ 20 permanent teeth excluding 3rd molars.

  • In good general health as evidenced by medical history (ASA Class I or II) per thepractitioner.

  • Planned to receive periodontal care for Generalized Stage II-III, Grade A-Cperiodontitis (previously Generalized Moderate to Severe Periodontitis) and aminimum of two quadrants of SRP (CDT code 4341) in practices participating in theNational Dental PBRN.

  • Willing to comply with all study visits and be available for the duration of thestudy (12-15 months)

  • Willing to provide contact information for self, including a cellular phone numberfor study text, and one to two emergency contacts to be reached for the follow-upvisits and any other study-related matters for the duration of the study.

Exclusion

Exclusion Criteria:

  • Known drug allergy to any antibiotics or anesthetics.

  • Use of systemic antibiotics taken within the previous 3 months prior to enrollment.

  • Medical condition which requires antibiotic prophylaxis prior to dentaltreatments/visits.

  • Current use of medications that, in the opinion of the practitioner, may causeadverse effects with AMXM (such as disulfiram, warfarin, and oral contraceptives).

  • History of any periodontal therapy (including SRP D4341, D4342) within the last 6months prior to enrollment.

  • Is currently pregnant or lactating per patient participant self-report.

  • Is considered immunocompromised, in the opinion of the practitioner (includingdiseases and conditions such as HIV/AIDS, immunosuppressive drug therapy and/orradiation), or has chronic mucosal lesions (e.g. pemphigus vulgaris) affecting thegingiva.

  • Has Diabetes mellitus with an HbA1c score of >/= 10% within the past 3 months as perpatient participant self-report.

Study Design

Total Participants: 544
Treatment Group(s): 3
Primary Treatment: Placebo
Phase: 3
Study Start date:
April 25, 2024
Estimated Completion Date:
May 26, 2026

Study Description

Précis: Periodontitis is a bacterial inflammatory disease and antibiotic use is being empirically used as part of its treatment. However, a clinical practice guideline on periodontal treatment adjuncts published in 2015 identified weak evidence on the use of systemic antibiotics and large heterogeneity across small scale studies, suggesting that larger pragmatic clinical trials would benefit clinical decision making. This will be a prospective, randomized, placebo-controlled trial, stratified by practice and practitioner. The study will investigate the effectiveness of adjunctive antibiotics as adjunct to scaling and root planing (SRP) compared to SRP with placebo for the treatment of generalized stage II-III, grades A-C periodontitis in approximately 544 patient participants from about 34 National Dental PBRN practices. Periodontal data will be collected at baseline, re-evaluation (6 weeks), and final (12 months) study visits. Changes in periodontal clinical and patient-reported outcomes will be assessed to determine the effectiveness of SRP plus adjunctive systemic Amoxicillin / Metronidazole antibiotics (AMXM) versus SRP with Placebo.

Objectives and Outcomes: Primary: The primary objective will assess the effectiveness of SRP plus adjunctive antibiotics compared to SRP with placebo in periodontitis individuals from baseline to 6 weeks and 12 months following non-surgical periodontal therapy (NSPT) as determined by changes in site-level periodontal probing depth (PD).

Secondary: To assess changes in: i) gingival inflammation (measured by bleeding on probing (BoP)), ii) periodontal tissue attachment (measured by clinical attachment level (CAL)), iii) reduction in diseased sites (measured by remaining sites with maximum probing depth ≥5 mm), and iv) disease remission (measured by number of participants with ≤4 sites with PD≥ 5mm); comparing SRP plus AMXM to SRP with a placebo adjunctive in periodontitis individuals from baseline to re-evaluation (6 weeks) to final (12 month) study visit following intervention. The patient-reported impact of periodontal treatment (measured by the Oral Health Impact Profile-5 (OHIP-5)) and treatment-related adverse events between groups will also be assessed.

Population: The sample size will be a target of approximately 544 patient participants enrolled from approximately 34 National Dental PBRN practices. All patient participants are indicated to receive SRP and have been diagnosed with periodontitis stages II-III, grades A-C.

Description of Intervention: The intervention will involve either SRP, which is considered the standard of care treatment for debriding root surfaces, in conjunction with 500 mg Amoxicillin and 500mg Metronidazole orally every 8 hours (q8h) for ten days following SRP or SRP with placebo.

Connect with a study center

  • University of Alabame

    Birmingham, Alabama 35233
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.